On January 9, 2026, USPTO Director John A. Squires designated four recent discretionary-denial rulings as precedential and ...
Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.
The European regulator’s anniversary year featured first-in-class therapies, rare-disease advances, safety warnings, and new ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...
FastWave Medical used 2025 to make uncommon progress for an early-stage company, advancing not one but two differentiated IVL ...
National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced changes in leadership across multiple ...
Munich Airport opens its new Terminal 1 Pier in April, adding non-Schengen capacity, premium lounges, and modernized ...
Background Why alcohol-associated liver disease (ALD) resolves after abstinence in most people but progresses to liver ...
Anthropic has announced a new tool that brings Claude Code’s advanced capabilities to less tech-savvy users, letting them ...
Once built to serve aircraft schedules, cargo terminals are emerging as strategic assets reshaping major air freight hubs.
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results